Company: SFA Therapeutics
Job title: Chief Scientific Officer
Mark Feitelson is co-founder of SFA Therapeutics; Professor at Temple University, expert in hepatitis and liver cancer; prior research at Jefferson Fox Chase & Stanford University. PhD, David Geffen School of Medicine at UCLA, B.S. Biology, University of California, Irvine.
Dr Feitelson received his Ph.D. in Microbiology and Immunology from the UCLA School of Medicine in 1979. He was then an American Cancer Society Postdoctoral Scholar at Stanford University (1980-82), and was the recruited to the Fox Chase Cancer Center by Baruch S. Blumberg (Nobel Laureate 1976) to work on the molecular pathogenesis of chronic hepatitis B. In 1991, Dr. Feitelson moved to Thomas Jefferson University, and in 2007, he became Professor of Biology at Temple University. He has over 120 publications, has been funded by NIH for more than 30 years, and has developed cell based and animal models capable of evaluating both the basic biology of HBV, its relationship to liver cancer, and evaluating new treatment approaches. He holds visiting professorships at several universities in China and lectures widely to students and scientists worldwide.